Literature DB >> 9322881

Comparative clinical pharmacology of cisplatin and carboplatin.

D J Murry1.   

Abstract

The platinum compounds cisplatin and carboplatin are active against a wide range of adult and pediatric malignancies. Whereas both exert their cytotoxic effect by incorporating into DNA, they have substantially different systemic and cellular pharmacology. In addition, their toxicity profiles are much different. Substantial interpatient pharmacokinetic variability and narrow therapeutic indexes of the two agents led to the development of several dosing strategies. Although these strategies reduce pharmacokinetic variability, their effect on improving patient outcome remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322881

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

1.  Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA.

Authors:  C Kloft; C Eickhoff; K Schulze-Forster; H R Maurer; W Schunack; U Jaehde
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures.

Authors:  A I Qureshi; M F Suri; J Khan; M Sharma; K Olson; L R Guterman; L N Hopkins
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

3.  Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.

Authors:  Teppei Yamaguchi; Sakurako Uozu; Sumito Isogai; Masamichi Hayashi; Yasuhiro Goto; Toru Nakanishi; Kazuyoshi Imaizumi
Journal:  Support Care Cancer       Date:  2016-12-13       Impact factor: 3.603

4.  Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.

Authors:  Shahbal B Kangarloo; Suman B Gangopadhyay; Rachel M Syme; Johannes E A Wolff; Stefan Glück
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

5.  Early Mechanisms of Chemoresistance in Retinoblastoma.

Authors:  Michelle G Zhang; Jeffim N Kuznetsoff; Dawn A Owens; Ryan A Gallo; Karthik Kalahasty; Anthony M Cruz; Stefan Kurtenbach; Zelia M Correa; Daniel Pelaez; J William Harbour
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

6.  Quantifying Drug-Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model.

Authors:  Chiara Fornari; Lenka Oplustil O'Connor; Carmen Pin; Aaron Smith; James W T Yates; S Y Amy Cheung; Duncan I Jodrell; Jerome T Mettetal; Teresa A Collins
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-10-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.